Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 2006, p. 3346-3351, Vol. 44, No. 9
0095-1137/06/$08.00+0 doi:10.1128/JCM.02631-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Centre for International Child Health, Department of Paediatrics, University of Melbourne, Melbourne, Australia,1 Fiji School of Medicine, Suva, Fiji,2 Microbiological Research Unit, Murdoch Children's Research Institute, Melbourne, Australia,3 Microbiology, The Children's Hospital at Westmead, Sydney, Australia,4 Fiji Pneumococcal Project, Ministry of Health, Suva, Fiji,5 Child Health and Vaccinology, London School of Hygiene and Tropical Medicine, London,United Kingdom,6 Murdoch Children's Research Institute, Melbourne, and Menzies School of Health Research, Charles Darwin University, Darwin, Australia7
Received 19 December 2005/ Returned for modification 22 February 2006/ Accepted 3 May 2006
|
|
|---|
|
|
|---|
Blood must be either defibrinated during collection or collected in bags containing anticoagulant to prevent clot formation. The most commonly used anticoagulant is citrate phosphate dextrose. Citric acid is often used in the food industry to inhibit the growth of bacteria (8, 9) and is therefore thought to be unsuitable for use in culture media. Commercial animal laboratories in developed countries use magnetic stirrers to defibrinate blood during collection. This specialized equipment is not easily obtained in developing countries, and the only other option for obtaining large volumes of defibrinated animal blood is to kill the animal, which is not practical or acceptable in most countries, and the blood is often contaminated. The importation of large quantities of defibrinated sheep or horse blood or the use of commercially made agar plates is also not an economically viable option for developing countries. The noncommercial collection of defibrinated animal blood requires a sterile glass bottle with glass beads or rods in situ. The bottle is manually rotated as the blood is collected so that the fibrin coats the glass beads and clot formation is prevented; this is also not a practical strategy for the collection of large volumes of blood.
In Fiji, where human blood agar is used routinely in the diagnostic bacteriology laboratory, we were unable to establish a reliable source of defibrinated sheep blood for our research laboratory. However, we could easily and reliably collect large volumes of sheep blood in commercially available human blood donor packs (which come together with a venipuncture needle and relevant tubing) containing citrate phosphate dextrose. We therefore aimed to compare blood agar prepared by using citrated human blood, citrated sheep blood, and defibrinated, noncitrated sheep blood with commercially available defibrinated, noncitrated horse blood agar. We tested each of these agars for their performance characteristics for the growth and antibiotic susceptibility testing of reference and clinical strains of S. pneumoniae, S. pyogenes, and S. aureus.
|
|
|---|
Laboratory methods. Each strain was cultured in serial dilutions prepared in brain heart infusion on each of four agars: defibrinated horse blood agar (HBA; Oxoid Ltd., Hampshire, United Kingdom), defibrinated sheep blood agar (DSBA), citrated sheep blood agar (CSBA), and citrated human blood agar (HuBA) plates. Each dilution of each organism on each blood agar was tested in triplicate at both laboratories. In an attempt to mimic the isolation of bacteria from a clinical sample, we repeated the same experiments using serial dilutions of the same organisms in a sample of sterile cerebrospinal fluid (CSF) obtained from a patient who had been admitted to RCH for a revision of his ventriculoperitoneal shunt. At CWMH, the CSF, obtained from a patient with suspected meningitis, had a normal appearance by microscopy and no growth on culture. Finally, we compared DSBA, CSBA, and HuBA for use in antibiotic susceptibility testing for S. pneumoniae and S. pyogenes.
Blood collection and medium preparation. At CWMH, citrated and defibrinated sheep blood were collected by an aseptic technique from healthy sheep who were not receiving antibiotics at the time of blood collection. The defibrinated blood was collected in a sterile glass bottle containing glass rods that were manually rotated. Four hundred fifty milliliters of sheep blood was collected in a standard, sterile blood donor bag (Baxter Healthcare) containing 63 ml of citrate phosphate dextrose as an anticoagulant. Following collection, the blood was immediately chilled and transported to the CWMH laboratory, where 10 ml of blood was transferred aseptically into BacTalert (Biomerieux, Inc, Durham, NC) bottles and incubated for 7 days to ensure sterility. Expired human blood that had been collected from numerous donors in an aseptic manner and that had been stored at between 2 and 8°C was pooled and obtained from both hospitals' blood banks. Fifty-six millimeters of citrated sheep blood was added to 1 liter of agar. The blood agar plates were prepared by standard methods (Oxoid Australia Pty. Ltd). Columbia (Oxoid Ltd.) agar base was used for initial growth, and Mueller-Hinton (Oxoid Ltd.) agar was used for sensitivity testing. The agar plates were stored at 2 to 8°C until they were required.
At RCH, an expired human blood pack containing 63 ml of citrate phosphate dextrose was obtained from one donor. The citrated sheep blood and the defibrinated sheep blood were obtained from a commercial supplier (Institute of Medical and Veterinary Science, South Australia). The medium was prepared according to the methods of CWMH (Oxoid Australia Pty. Ltd.). The defibrinated HBA was made commercially (Oxoid Ltd.).
Strains and dilutions.
Three S. pneumoniae strains were used: strains ATCC 49619 (serotype 19F) and ATCC 6305 (serotype 5) and a clinical isolate (serotype 1, isolated from a blood culture). Three S. aureus strains were used: strains ATCC 25923 and ATCC 29213 and a clinical isolate (isolated from a blood culture). Two S. pyogenes strains were used: strain ATCC 19615 (emm type 80) and a clinical isolate (emm type 1, isolated from a blood culture). Each strain was inoculated in brain heart infusion (Oxoid Ltd.) broth to make a suspension equal to a 0.5 McFarland standard (
1.2 x 108 CFU/ml). These were serially diluted before 100 µl was plated in triplicate on each agar. Similarly, each strain was serially diluted in CSF before it was plated in triplicate on each agar. The inoculated plates were incubated at 35°C in 5% CO2 for 18 to 20 h. The results were recorded in terms of viable counts, colony morphology (by description and photographs), and colony size (recorded in millimeters at the widest margin).
Antibiotic susceptibility testing. Susceptibility testing was performed at CWMH only. Susceptibility testing for S. aureus was not performed, as blood is not required as a medium supplement for this organism. To test susceptibility, 0.5 McFarland standard concentrations were made in triplicate from S. pneumoniae strains ATCC 49619 and ATCC 6305 and a clinical isolate from a normally sterile site and from S. pyogenes strain ATCC 19615 and a clinical isolate from a normally sterile site. According to the methods of the CLSI (formerly the NCCLS) (6, 7), each sample was inoculated onto three different blood Mueller-Hinton (Oxoid Ltd.) plates. Disks containing oxacillin at 1 g, erythromycin at 15 g, chloramphenicol at 30 g, and co-trimoxazole at 1.25 g (Difco, Sparks, MD) were applied along with an optochin disk for the pneumococcal isolates. Disks containing penicillin at 1 g, erythromycin at 15 g, chloramphenicol at 30 g, and vancomycin at 30 g (Oxoid Ltd.) were applied for the S. pyogenes isolates. All plates were incubated overnight in 5% CO2 at 35°C. Zone diameters were read following 24 h if incubation. Two scientists read the plates independently.
|
|
|---|
S. pneumoniae. The numbers of colonies of the S. pneumoniae reference strains were similar on all blood agars at all dilutions, including the strains in CSF (Table 1). In addition, the growth of a clinical isolate of S. pneumoniae was similar on all blood agars at all dilutions and in CSF (data not shown). The morphological appearances were similar for colonies on HBA, CSBA, and DSBA. However, colonies were much smaller and alpha-hemolysis was not obvious for any strain on HuBA (Table 2; Fig. 1). Additional photographs are available on the http://www.rch.org.au/cich/pubs/ website.
|
View this table: [in a new window] |
TABLE 1. Colony counts of strains tested on four different blood agar plates
|
|
View this table: [in a new window] |
TABLE 2. Appearances of colonies and zones of hemolysis for tested strains on four different blood agar plates
|
![]() View larger version (80K): [in a new window] |
FIG. 1. Growth of S. pneumoniae ATCC 6305 on the four different blood agars at a dilution of 1 x 101 CFU/ml.
|
![]() View larger version (90K): [in a new window] |
FIG. 2. Growth of S. aureus ATCC 25923 on the four different blood agars at a dilution of 1 x 102 CFU/ml.
|
![]() View larger version (95K): [in a new window] |
FIG. 3. Growth of Streptococcus pyogenes ATCC 19615 on the four different blood agars at a dilution of 1 x 102 CFU/ml.
|
|
View this table: [in a new window] |
TABLE 3. Antibiotic disk susceptibility results for three S. pneumoniae strains
|
|
View this table: [in a new window] |
TABLE 4. Antibiotic disk sensitivity results for three S. pyogenes strains
|
|
|
|---|
To our knowledge, this is the first time that HuBA has been shown to be suboptimal for the growth and susceptibility testing of S. pneumoniae, S. aureus, and S. pyogenes. The only published comparison of HBA, DSBA, and anticoagulated human blood agar that we could find was a study that compared the isolation of Bordetella pertussis on different blood agars (4). That study demonstrated that HuBA was inferior to defibrinated horse and sheep blood agar. It is not clear why HuBA is inferior to agar with other animal blood. It has been suggested that human blood may contain antibiotics, antibodies, or other anti-infective agents (5). The lack of hemolysis on human blood agar may be due to the age of the red cells in the expired human blood or some other factor.
By contrast, we were able for the first time to describe a practical alternative to human bloodcitrated sheep bloodthat most countries should be able to adapt without requiring a major investment in infrastructure. Citrate is said to have antibacterial characteristics (8, 9), but we found that CSBA performed similarly in most aspects to DSBA. Other studies have demonstrated that defibrinated pig blood and goat blood are suitable alternatives for medium supplements for S. pneumoniae (1, 3), raising the possibility that citrated blood from animals other than sheep may also be acceptable. In our experience, it is the collection of defibrinated blood rather than the availability of the animal that has posed the most difficult hurdle in providing a sustainable supply of blood.
We are confident that CSBA may be used for the isolation of all three organisms tested in this study. Our study evaluated a citrate to blood ratio of 1:10. It is not known whether a ratio lower than this may affect the growth and sensitivity pattern of the organisms; therefore, care needs to be taken at the point of collection to ensure that the correct ratio of blood is collected.
Hu MHA plates, which are used routinely in developing countries, cannot be recommended for use for the isolation or susceptibility testing of any of these organisms, which supports existing recommendations (1, 2, 3, 5). A strategy is required to phase out its use. Further work is required to assess whether CSB MHA is suitable for antibiotic susceptibility testing for S. pneumoniae. Preliminary data suggest that it is likely to perform better than Hu MHA. Our results did not confirm that CSB MHA plates could be used for susceptibility testing for S. pyogenes. Further work is required to assess whether CSBA and CSB MHA are suitable for the isolation and susceptibility testing, respectively, of a larger range of organisms. This will determine whether they could be recommended as practical alternatives for universal use.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»